beat/rais humira storm
remain neutral rate share follow morn earn
updat humira manag anoth quarter upsid vs consensu leverag
across busi remain appar manag also indic grow headwind
think portend meaning downward revis consensu put
take across busi impact margin stock remain larg
marri prospect humira note europ like pressur
manag anticip see still underappreci volum share
drag us continu prefer sidelin name
beat non-gaap ep beat consensu pjc solid
revenu upsid consensu pjc humira revenu
beat consensu pjc least partli driven
unquantifi stock benefit launch new formul us
imbruvica also beat vs consensu pjc hcv franchis
miss vs consensu pjc expens disciplin help
ep beat opex lower consensu pjc
guidanc rais somewhat milquetoast implic great either
non-gaap ep guidanc rais midpoint midpoint
beat quarter implic
miss impli non-gaap ep consensu also note
manag guid doubl digit ep growth indic ep could
low leav lot room downsid current consensu
humira concern feel like broken record humira face intern
headwind compet four biosimilar survey feedback indic substanti
pressur greater eros predict eu biosimilar option continu
view franchis increasingli riski manag seem confirm lower
ex-u humira guidanc cite wors expect price eros
commentari us trend sanguin sure recent
survey feedback indic faster anticip share eros
remain sidelin lower humira estim level
meaning consensu elsewher take hcv estim
given leverag busi model anticip dramat impact
ep lower price target deriv appli
multipl previous ep discount back name
primarili trade prospect humira remain neutral rate
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
